LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Inicio・Lista de Acciones・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Cerrado

SectorSanidad

12.75 6.07

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.81

Máximo

12.93

Métricas clave
By Trading Economics
Ingresos	4.4M -18M
Ventas	3.4M 18M
Margen de beneficios	-99.678
Empleados	131
EBITDA	5.6M -15M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+40.96% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	193M 332M
Apertura anterior	6.68
Cierre anterior	12.75

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

78 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

5.04 / 5.44 Soporte y Resistencia

ENANTA PHARMACEUTICALS INC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 nov 2025, 18:59 UTC

Principales Movimientos del Mercado

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Charlas de Mercado

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Charlas de Mercado

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Charlas de Mercado

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Ganancias

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Ganancias

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Ganancias

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Ganancias

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Ganancias

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Ganancias

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Charlas de Mercado

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Charlas de Mercado

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Charlas de Mercado

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Adquisiciones, fusiones, absorciones

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Ganancias

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Adquisiciones, fusiones, absorciones

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Adquisiciones, fusiones, absorciones

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Charlas de Mercado

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparación entre iguales

Cambio de precio

ENANTA PHARMACEUTICALS INC previsión

Precio Objetivo

By TipRanks

40.96% repunte

Estimación a 12 Meses

Media 17 USD 40.96%

Máximo 24 USD

Mínimo 9 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.04 / 5.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

78 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.